XTL Biopharmaceuticals Acquires AI Data Firm Social Proxy
Ticker: XTLB · Form: 6-K · Filed: Aug 14, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Aug 14, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $430,000, $1.00, $1.20, $1,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, ai, data-extraction, strategic-pivot
TL;DR
XTL Bio just bought an AI data company, Social Proxy. Big pivot incoming?
AI Summary
On August 14, 2024, XTL Biopharmaceuticals Ltd. announced the completion of its acquisition of The Social Proxy Ltd., an AI web data company. The transaction involved the issuance of XTL Biopharmaceuticals Ltd. shares in exchange for all of Social Proxy's share capital.
Why It Matters
This acquisition signals XTL Biopharmaceuticals' strategic move into the AI and data extraction sector, potentially expanding its business model beyond its traditional biopharmaceutical focus.
Risk Assessment
Risk Level: medium — The acquisition represents a significant strategic shift for XTL Biopharmaceuticals, introducing new business lines and potential integration challenges.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Acquiring company
- The Social Proxy Ltd. (company) — Acquired company
- August 14, 2024 (date) — Date of acquisition announcement
FAQ
What is the primary business of The Social Proxy Ltd.?
The Social Proxy Ltd. is an AI web data company that develops and powers an ethical, IP-based proxy and data extraction platform for AI and BI applications.
What was the nature of the transaction between XTL Biopharmaceuticals and Social Proxy?
XTL Biopharmaceuticals completed the acquisition of all issued and outstanding share capital of Social Proxy.
When was the acquisition of Social Proxy announced as completed?
The acquisition was announced as completed on August 14, 2024.
What is XTL Biopharmaceuticals Ltd.'s principal executive office location?
XTL Biopharmaceuticals Ltd.'s principal executive offices are located in Ramat Gan, Israel.
What type of filing is this document?
This document is a Form 6-K, a Report of Foreign Private Issuer.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-08-14 09:15:56
Key Financial Figures
- $430,000 — the Company, and (ii) the payment of US$430,000 to the shareholders of Social Proxy.
- $1.00 — to purchase ADSs at a purchase price of $1.00 per ADS and accompanying warrant. The w
- $1.20 — The warrants have an exercise price of $1.20 per ADS and shall be exercisable during
- $1,500,000 — . The Company raised gross proceeds of $1,500,000 in the private placement. The private
Filing Documents
- ea0211391-6k_xtlbio.htm (6-K) — 17KB
- ea021139102ex99-1_xtlbio.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-068639.txt ( ) — 41KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 14, 2024 XTL BIOPHARMACEUTICALS LTD. By: /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 2